Analyst consensus rating

Xilio Therapeutics Analyst Rating: Strong Buy

Direct answer

Xilio Therapeutics's consensus rating is Strong Buy.

2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $18.00.
Forecast evidence checked November 16, 2026.

Get free Xilio Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$8.08
Average price target
$18.00
High price target
$20.00
Low price target
$16.00
Low target gap
+98.1%
Target upside
+122.9%
High target gap
+147.7%
Target range width
49.5%
Consensus rating
Strong Buy
Analysts
2
Evidence date
November 16, 2026
Valid through
November 23, 2026

Read the frequently asked questions.

What is the analyst consensus rating for Xilio Therapeutics?

Xilio Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $18.00.

How far are Xilio Therapeutics's low and high targets from the recorded price?

The low target implies +98.1%, while the high target implies +147.7%.

How many analysts are included in Xilio Therapeutics's consensus?

The verified consensus includes 2 analysts.

How is Xilio Therapeutics's target upside or downside calculated?

The average target of $18.00 is divided by the recorded price of $8.08, then one is subtracted to produce +122.9%. This does not guarantee a future return.

When was Xilio Therapeutics's analyst forecast verified?

The data was verified on 2026-11-16. The dataset is valid through 2026-11-23.